文献速递妇产影像US

妊娠后持续增强肌层血管与hCG的关联

Association of human chorionic gonadotropin and post-pregnancy persistent enhanced myometrial vascularity.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-06-29

hCG降至非妊娠水平中位时间97天,EMV消退中位时间113天。作者认为hCG的血管扩张与促血管生成作用可能维持EMV,支持血流动力学稳定者期待管理。

要点

  • 持续EMV常伴hCG长期可测,鉴别先天动静脉畸形与无EMV的妊娠物残留
  • Doppler PSV≥20 cm/s视为升高,高PSV提示干预后出血风险
  • 血流动力学稳定者可考虑期待管理,监测hCG与PSV有助于分层

核心结论

  • 妊娠后持续存在的增强肌层血管与循环hCG长期可测相关,hCG可能由残留滋养细胞产生
  • 持续EMV可能主要被循环hCG的血管扩张和促血管生成效应所维持
  • 识别这一关联为EMV自然病程提供生理学解释,并支持血流动力学稳定患者的期待管理

研究设计与样本

  • 回顾性观察性病例系列研究
  • 超声诊断EMV依据肌层内扩张血管网,伴或不伴妊娠物残留
  • 监测系列母体血清hCG,记录最高hCG水平及hCG降至≤5 mIU/mL的时间

关键影像表现/征象

  • 超声可见肌层内扩张血管网,伴或不伴妊娠物残留,持续超过妊娠终止后4–6周
  • Doppler测得血管网内最高PSV中位80.8 cm/s,13例测得PSV均升高
  • EMV消退中位时间113天,范围为58–293天
  • hCG降至非妊娠水平中位时间97天,范围为58–271天

诊断标准与关键数值

  • EMV持续定义为妊娠失败或终止后肌层内扩张血管网持续超过4–6周
  • hCG非妊娠水平定义为≤5 mIU/mL
  • Doppler PSV≥20 cm/s视为升高
  • 超声正常表现、EMV解决的相关操作实施或hCG达非妊娠水平时可判断EMV消退

临床应用与阅片要点

  • 持续EMV需与先天性动静脉畸形及不伴EMV的妊娠物残留相鉴别
  • 高PSV可提醒临床医生警惕干预后出血风险
  • 血流动力学稳定患者可考虑期待管理,减少侵入性操作

局限性

  • 回顾性观察性病例系列设计

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To explore the role of circulating human chorionic gonadotropin (hCG) in the pathophysiology of enhanced myometrial vascularity (EMV) postpregnancy and the usefulness of determining hCG level in the clinical evaluation and management of this condition.

METHODS: This was a retrospective observational case series of patients managed clinically at our centers who had postpregnancy EMV diagnosed using ultrasound by the observation of a dilated vascular web in the myometrium, with or without retained products of conception (RPOC), that persisted beyond 4-6 weeks following a failed or terminated pregnancy. We retrieved serial maternal serum hCG measurements and noted the highest maternal serum hCG level measured, as well as the time for hCG to reach non-pregnancy levels, defined as hCG ≤ 5 mIU/mL. The time to resolution of the EMV was recorded; this was determined by normal ultrasound findings (when imaging was available), or assumed if a procedure had been performed to resolve the EMV or when hCG reached non-pregnancy levels. When available, we retrieved peak systolic velocity (PSV) values measured in the vascular web. A PSV of ≥ 20 cm/s was considered elevated. Representative ultrasound and color Doppler images were evaluated.

RESULTS: Sixteen patients with sonographically diagnosed EMV that was still present over 4-6 weeks after failure or termination of a pregnancy (i.e. persistent EMV) were included. The median duration from diagnosis of EMV until resolution was 113 (range, 58-293) days. Persistence of EMV was associated with prolonged detectable levels of hCG, with a time for hCG to reach non-pregnancy levels of 97 (range, 58-271) days. In the 13 cases in which this was measured, Doppler studies revealed elevated PSV, with a median highest PSV of 80.8 (range, 46.7-146.3) cm/s. One patient was managed expectantly from the outset of their presentation. Four additional patients were followed expectantly for the EMV after they underwent surgical procedures at presentation; seven patients required uterine artery embolization and four required dilatation and curettage to remove the residual placental tissue.

CONCLUSIONS: Our findings suggest that pathological persistence of EMV is associated with the prolonged presence of circulating hCG, probably produced by residual trophoblastic tissue. Furthermore, we believe that persistent EMV is potentially maintained, in major part, by the vasodilatory and angiogenic effects of circulating hCG. Recognition of this association provides a physiological explanation for the natural history of EMV and supports expectant management in hemodynamically stable patients. Monitoring of maternal serum hCG and Doppler PSV may help to distinguish self-resolving EMV from cases requiring intervention, and high PSV levels can alert the practitioner to the potential for hemorrhage following intervention. These findings highlight the importance of differentiating EMV from congenital arteriovenous malformation and RPOC without EMV, and may inform more tailored, less invasive clinical management strategies. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Timor-Tritsch, Monteagudo, Platt, et al. Association of human chorionic gonadotropin and post-pregnancy persistent enhanced myometrial vascularity. Ultrasound Obstet Gynecol. 2026. PMID: 42373088. doi:10.1002/uog.70266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。